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Aerva lanata (L.) Juss. ex Schult., is one of the medicinal plants widely used by traditional healers for the treatment 
of urolithiasis. A perusal of literature revealed that no studies have so far been undertaken to evaluate its efficacy 
against Calcium Hydrogen Phosphate Dihydrate (CHPD) or brushite type urinary crystals. Hence, an attempt is 
made in this study to assess the validity of this indigenous knowledge by using in vitro single diffusion gel growth 
technique. The morphology of CHPD crystals was studied by microscopy. The structural and chemical changes of 
the treated crystals were assessed by FTIR, XRD, TGA/DTA and SEM/ EDX analysis. The study revealed that 
aqueous extract of Aerva lanata is very effective to make structural changes and reduction in size of the brushite 
type urinary crystals. 
Keyword: Urolithiasis, Aerva lanata, Calcium Hydrogen Phosphate Dihydrate, SEM, EDX, FT-IR, TGA/DTA and 
XRD. 
1. Introduction
Urolithiasis is a common clinical condition 
referred to as kidney stone and it affects 12% of 
the world population [1]. The disease frequency is 
on the rise due to imbalanced life style, mental 
stress, lack of physical exercise, unnatural dietary 
habits and dilution of life sustaining natural 
processes. In modern medicine, drugs without 
side effects are not available to 
disintegrate/dissolve urinary stone [2]. In the 
indigenous system of medicine, there are many 
reports regarding the efficacy of phyto-medicines 
for the treatment of urinary stones. Aerva lanata 
(L.) Juss. ex Schult., is one such  medicinal plant 
widely recommended by traditional healers for 
the treatment of urolithiasis [3]. Either whole plant 
or shoots /roots are used as a single drug in 
traditional medicine [4]. In the present 
investigation, we aim to assess the validity of this 
indigenous knowledge by conducting in vitro 
crystallization experiments based on reverse 
pharmacological approach [5]. The study aims to 
explore the synergetic action of phyto- chemicals 
in the aqueous shoot extract of Aerva lanata on in 
vitro growth inhibition of CHPD (brushite type) 
urinary crystals.  
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2.  Materials and Methods 
An ethnobotanical survey was conducted among 
the traditional healers and herbal collectors of 
Kottayam district to document their traditional 
knowledge on antiurolithiatic medicinal plants. 
60% of the respondents suggested that Cherula 
[Aerva lanata (L.) Juss. ex Schult] is as effective 
as Kalloorvanchi [Rotula aquatica Lour.] to 
disintegrate urinary stones [3]. Hence, Cherula 
[Aerva lanata (L.) Juss. ex Schult] was selected 
for the in vitro validation of its traditional 
antiurolithiatic property. The plant specimens 
were collected from CMS college campus and 
authenticated in the Department of Botany, CMS 
College, Kottayam. The voucher specimen 
(accession no: 3402) is deposited in the CMS 
Herbarium, C.M.S. College, Kottayam. The aerial 
parts of the plant were cleaned in tap water, shade 
dried and powdered. The aqueous extract (40 
mg/ml) with appropriate dilution was used for 
further in vitro inhibition studies on 
CHPD/brushite type urinary crystals. The 
proportions of additive [Aerva lanata shoot 
extract (Als)], with respect to CaCl2 and double 
distilled water used in different treatments are as 
follows:  
 Treatment 1 (Control) - 5 ml CaCl2 : 5 ml 
water  
 Treatment 2 (ALS1) - 5 ml CaCl2 : 1 ml Als : 
4 ml water  
 Treatment 3 (ALS2) - 5 ml CaCl2 : 2 ml Als : 
3 ml water  
 Treatment 4 (ALS3) - 5 ml CaCl2 : 3 ml Als : 
2 ml water  
 Treatment 5 (ALS4) - 5 ml CaCl2 : 4 ml Als : 
1 ml water  
 
2.1 Single diffusion gel growth technique:  
The antiurolithiatic property of Aerva lanata was 
verified by the growth dissolution studies of 
Calcium Hydrogen Phosphate Dihydrate 
(CHPD), employing hydrogel method developed 
by Henisch et al. (1998) [6], with appropriate 
modifications as suggested by Rajendran and 
Dale (2010) [7] and Parekh et al. (2007) [8]. The 
hydrogel was prepared from Sodium Metasilicate 
(Na2SiO3.9H2O, m.wt.284 g/mol) and specific 
gravity of the gel was adjusted to 1.06 using 
deionized water. Freshly prepared CaCl2 
solutions were used for growing CHPD crystals. 
The pH of the gel solution was adjusted to 6.5 by 
adding one molar Orthophosphoric acid. The gel 
thus prepared was used as a medium for growing 
crystals employing sterile Petri- plates and Test 
tubes. 
The initial stages of crystal growth were studied 
by microscopic observation of the CHPD crystals 
grown in the micro-slides. A drop of solution 
prepared for gel was put at the middle of a sterile 
micro slide and it was kept inside a sterile Petri 
dish. The gel is then covered with cover slip and 
allowed to set slowly. Thereafter, suitable 
concentration of the calcium chloride solution 
was poured up to the level of the cover slip. The 
poured solution was allowed to diffuse slowly 
through the gel to initiate nucleation, aggregation 
and growth of micro-crystals. Different 
concentrations of the Als extract were then added 
to calcium chloride to study the growth inhibition 
and dissolution of CHPD crystals. The slides 
were observed after 5 minutes using a compound 
microscope (Olympus); the photographs were 
taken and were subjected to morphometric 
analysis using image analyzer software. 
CHPD crystal growth inhibition studies were also 
conducted in sterile test tubes. For that, 10ml of 
the gel solution was poured in and was allowed to 
set slowly at room temperature. Equal volume of 
Calcium chloride solution was added into each 
tube. Different concentrations of the Als extract 
(I%  to 4%) were then added through the sides of 
the test tubes and the inhibitory effects were 
analyzed based on the changes noted with respect 
to number, size and morphology of crystals. After 
3 weeks, the crystals were harvested from the gel, 
washed in double distilled water, filtered and then 
air dried. The dried crystals were characterized by 
SEM/EDX, FTIR, TG/DTA and XRD techniques.  
 
3.  Results and Discussion 
The results of the present study revealed the 
synergetic action of bioactive compounds of 
Aerva lanata on in vitro growth inhibition of 
calcium phosphate urinary crystals (Fig. 1 and 
Fig. 2). With increasing concentration of the 
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shoot extract (Als1-Als4) a gradual reduction in 
the size with alteration in the morphology of 
crystals were observed (Table 1). The 
morphology of the crystal formed in the control 
(star & sword) gets altered into spindle, round or 
oval in the treatments ALS2 to ALS4.The 
interference with crystal growth and aggregation 
is a possible therapeutic strategy for prevention of 
recurrent stone diseases. It is suggested that, 
macro molecules of higher molecular weight of 
plant extracts exert their action similar to natural 
urinary inhibitors and inhibit crystal nucleation, 
growth and aggregation [9]. Moreover, the  
frequency of the sharp edged and larger crystals 
or crystal aggregates were much reduced in 
treatments (ALS1, ALS2, ALS3 & ALS4). This 
finding is in agreement with the results of earlier 
studies based on a glycoprotein inhibitor of 
calcium oxalate crystal growth [10, 11]. As pointed 
out by Parekh et al., (2007) [8] change in 
morphology of crystal is an important 
phenomenon because, if the painful star type or 
spiky, needle, irregular stones were converted 
into smooth spherical or oval grain like ones, 
then, their passage through the urethra is less 
painful.  
 
 
 
Fig 1: Harvested CHPD crystals 
 
 
 
 
Fig 2: Harvested ALS4 crystals 
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Table 1: Average apparent dimensions of the grown crystals in control and Als extract treatments 
 
S. No. Treatments Shape Area range (μm2) Average  number of crystals
1 
 
C (CHPD) 
 
 
Irregular 
Star 
Sword 
Leaf like 
 
38-4125 
 
4 
2 
 
ALS1 
 
 
Dumbbell 
Spindle 
Round 
Irregular 
3-358 9 
3 ALS2  
Spindle 
Oval 
Dumbbell
2-289 
 19 
4 ALS3  
Spindle 
Dumbbell 
Oval 
1- 203 38 
5 ALS4 
Round 
Dumbbell 
Spindle 
0.6– 117 43 
 
FT-IR spectra of the gel grown crystals (control-
CHPD and treatment-ALS4) are shown in Fig. 3. 
In the control (CHPD), the presence of water of 
crystallization was referenced from absorptions at 
3543.16, 3487.57 and 3282.79 cm-1, which are 
due to intermolecular and weakly H bonded OH. 
The absorption at 1650.29 cm-1 is due to H-O-H 
symmetric bending vibrations and P=O 
associated stretching vibrations were observed at 
wave numbers 1211.2, 1129.96 and 1064.34 cm-1. 
Likewise, the P-O-P asymmetric stretching 
vibrations were observed at 873.10 and 790 cm-1. 
The absorption at 665 cm-1 is due to (H-O-) P=O 
and the strong absorption at 578 and 525 cm-1are 
due to acid phosphates. The comparison of the 
FTIR spectra of ALS4 with that of control 
(CHPD) revealed similarity with most of the 
bands along with two additional bands at 2827 
cm-1 and 2884 cm-1, which indicate C-H stretch 
(alkanes).  Besides, it shows two shifts. The peak 
at 3282 cm-1 was shifted to a lower value at 3276 
cm-1; another peak at 1211 cm-1 was shifted to a 
higher value at 1214 cm-1. A shift from 3282 cm-1 
to 3276 cm-1 indicates new hydrogen bond 
formation between H-OH. The shift and 
appearance of two new peaks as mentioned above 
clearly indicate the incorporation of bioactive 
organic moiety of the Als (Aerva lanata shoot) 
extract within the crystal framework of CHPD. 
  
The X-ray diffractogram of the gel grown CHPD 
crystal (Fig. 4) matches with the JCPDS data (72-
0713). As it is evident from the Fig. 5, the XRD 
pattern of Als extract treated crystals (ALS4), 
shows shift in the peak positions, change in peak 
intensity and appearance of new peeks which 
shows the effectiveness of the Als extract to 
inhibit/reduce the growth and modify the crystal 
structure of CHPD crystals. 
The TG-DTA curve of CHPD shows weight loss 
in two stages (Fig. 6). The major weight loss of 
about 20% occurs between 123 ºC and 191 ºC 
which indicates the loss of water of hydration. 
The endothermic peak in DTA around 123 ºC 
with the associated shoulders indicates the 
stepwise removal of water during this 
temperature range. Subsequently in the high 
temperature range of 191-441  ºC, two molecules 
of CaHPO4 combine and result in the elimination 
of a water molecule leading to the formation of 
calcium pyrophosphate and nearly 74% of the 
sample was stable. The observed mass loss 
corresponds well with the DSC curve. The 
following chemical reactions are expected to 
occur during the dehydration and decomposition 
stages [12]. 
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Fig 3: FTIR of control-CHPD (C) and treatment (ALS) crystals 
  
 
Fig 4: XRD pattern of CHPD  
 
Fig 5: XRD pattern of ALS4 
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2CaHPO4.2H2O → 2CaHPO4 + 4 H2O↑ --- (1) 
 
2CaHPO4 → Ca2P2O7 + H2O↑ ------------ (2) 
 
The thermal degradation pattern of ALS4 crystals 
is not identical with that of CHPD (Fig. 7). In 
ALS4 crystals, the major weight loss of about 
21.5% occurs between 110 0C and 192 0C. The 
first stage shows 2 shoulders along with a 
prominent peak at 189 0C. Onset of the second 
stage is at 370 0C and it shows nearly 3.5% 
weight loss up to 480 0C and the rest of the 
sample (75%) was stable up to the temperature 
819 0C.  This altered pattern of TG/DTA curve of 
Aerva lanata shoot treated (ALS4) crystals 
suggests incorporation of bioactive compounds 
from the aqueous shoot extract of Aerva lanata.  
 
 
 
Fig 6: Thermogram of CHPD 
 
 
 
Fig 7: Thermogram of ALS4 
 
The results of the SEM analysis also revealed the 
basic structural changes of the Als treated crystals 
(Fig. 9) from pure CHPD crystals (Fig. 8).The 
SEM of CHPD crystals shows a continuous sheet  
like formation without any intermediate space 
whereas the SEM of ALS4 shows a network 
structure with lots of space in between.  
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Fig 8: SEM of CHPD crystals 
 
 
 
Fig 9: SEM of ALS4 crystals 
 
The Energy Dispersive X-ray Spectroscopy 
(EDX) analysis of Als treated crystals (ALS4) 
revealed the presence of 3.72% of Carbon atoms 
along with expected Oxygen (36.57%), 
Phosphorous (32.65%) and Calcium (27.06%) 
atoms (Fig. 10). The above data give additional 
evidence to support the incorporation of organic 
moiety from the Als extract (Table: 2). 
 
 
 
 
Table 2: Elemental analyses of CHPD & ALS4 
Element Pure CHPD ALS4(Atom %) (Atom %) 
C ------ 3.72 
O 20.84 36.57 
P 39.11 32.65 
Ca 40.05 27.06 
Total 100 100 
Ca/P 1.02 0.83 
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Fig 10: EDX of ALS4 
 
The CHPD/Brushite crystal has a plate-like 
morphology dominated by (010) faces and the 
structure within the (010) plane is composed of 
two corrugated rows of Ca 2+ and HPO4 2- that are 
offset in the <010> direction. Between these 
calcium and phosphate containing sheets, are 
layers of water molecules bound to the calcium 
ions above and below the (010) plane [13]. It is 
assumed that when the interconnecting layers of 
water molecules, that bound to the calcium ions 
above and below the (010) plane,  is  unavailable 
for bonding due to incorporation of bioactive 
compounds in Als extract, further  growth of 
CHPD crystals  may get arrested. This explains 
one of the possible mechanisms for the efficacy 
of Als extract on growth inhibition of CHPD 
crystals under in vitro conditions.  The FTIR and 
TGA/DTA data provide additional evidence that 
organic moiety from Als extract might have 
formed a bond with -OH on the surface of (010) 
face of CHPD. The role of phytoactive 
compounds of Aerva lanata in reducing the 
aggregation of CHPD/ brushite type crystals is 
substantiated in the present investigation. It is 
assumed that incorporation of the bioactive 
compounds within the framework of CHPD 
might have blocked further growth and 
aggregation ALS4 crystals. In vivo studies 
conducted by Soundararajan et al. (2006) [14] and 
Selvam et al (2011) [15] further revealed that 
bioactive substances of Aerva lanata end up in 
the urine and exert their action to disintegrate 
calcium oxalate type of crystals too. In short, the 
findings of the present investigation along with 
earlier in vivo studies substantiate the traditional 
botanical knowledge of Aerva lanata as an 
excellent single drug for the treatment of 
Urolithiasis. 
 
4.  Summary 
The shoot extract of Aerva lanata was evaluated 
for its antiurolithiatic activity employing single 
diffusion gel growth technique. The 
morphological and structural examination of the 
treated CHPD crystals with optical/ scanning 
electron microscopy, FTIR, XRD and TGA/DTA 
analysis forms an evidence for the dissolution 
property of the bioactive compounds in shoot 
extract of Aerva lanata. The results of the present 
study provide conclusive evidence to corroborate 
the traditional botanical knowledge of the Aerva 
lanata as an effective antiurolithiatic agent. 
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